Antibody Drug Conjugates (ADC) Market

The global Antibody Drug Conjugates (ADC) market, valued at US$7.6 billion in 2022, is forecasted to grow at a robust CAGR of 15.2%, reaching US$9.7 billion in 2023 and an impressive US$19.8 billion by 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the market can be attributed to various factors such as including the growing prevalence of cancer, and increasing R&D activities for the development of novel ADCs by key market players. Antibody-drug conjugates represent a highly potent approach to treating cancer patients. They harness the precision of monoclonal antibodies, directing them towards specific antigens, to deliver potent cytotoxic drugs. This approach enhances drug effectiveness while minimizing the adverse effects typically associated with traditional chemotherapy.

Attractive Opportunities in the Antibody Drug Conjugates Market.

To know about the assumptions considered for the study, Request for Free Sample Report

Antibody Drug Conjugates Market Dynamics

Driver: Increased investment and collaborations by key market players for the development of novel ADCs

Antibody drug conjugate is a rapidly growing field. Significant investments are needed for R&D, clinical trials, and manufacturing of ADCs. Large biopharmaceutical companies are heavily investing in expansion of development and manufacturing capabilities for ADCs, deals including licensing and collaboration agreements and mergers between a big pharmaceutical company and a biotech firm specializing in antibody-based cancer therapies. According to data from Biomedtracker, between January 2018 and March 2023, there have been around 100 licensing deals for ADCs. There were only 4 ADC licensing agreements recorded in 2018, which reached 33 in 2022. 11 ADC-focused licensing deals were announced in the first three months of 2023. For instance, in April 2023, BioNTech signed a USD 170 million licensing deal with Duality Biologics (China) for exclusive access to two ADCs.

Restraint: Side effects associated with ADCs

ADCs have a reasonable side-effect profile due to high selectivity. Among the approved 11 ADCs, the most common severe side effect is hematotoxicity, which includes neutropenia, thrombocytopenia, leukopenia, and anemia. Hematotoxicity, combined with hepatotoxicity and gastrointestinal reactions, is probably induced due to the premature release of cytotoxic payloads into blood circulation. Moreover, the immune response induced by the antibody part of ADC may cause secondary injuries, resulting in nephrotoxicity. According to recent clinical observations, potential lung toxic effects like ILD have been observed during the ADC treatment period, particularly in anti-HER2 ADCs. Several death cases have been reported to be related to ILD during the clinical trials of T-DM1 and DS-8201. The detailed mechanism of action of ILD, however, remains unclear. Therefore, the corresponding optimizations of next-generations of ADC are expected to minimize side effects.

Opportunity: Adoption of combination therapies

Combination therapies utilizing antibody-drug conjugates offer significant market growth potential and are an appealing strategy for both existing and growing pharmaceutical & biotechnology businesses. ADCs have been actively studied in combination with other anticancer agents such as chemotherapy, targeted therapy, immunotherapy, and anti-angiogenic agents in recent years. The drug combinations including anti-angiogenic medicines, HER2-targeted medications, DNA damage response agents, and immune checkpoint inhibitors (ICIs) are currently in active research. More recently, strategies for combining immunotherapy with ADCs have also entered clinical studies. There is growing evidence that ADCs can improve immunotherapy efficacy by inducing immunogenic cell death, dendritic cell maturation, increased T-lymphocyte infiltration, enhanced immunological memory, and the production of immunomodulatory proteins such as PD-L1 and MHC.

Challenge: Technical complexities

ADCs comprise a tumor antigen-specific antibody, a potent cytotoxic payload and a stable chemical linker that joins the antibody to the cytotoxic drug. The individual characteristics and risks associated with these three components present unique challenges and pose considerable risks at multiple levels. Achieving an optimal balance between the potency of the cytotoxic drug and the specificity of the antibody is one of the major issues. Another challenge is the potential for toxicity, particularly in non-target tissues. The cytotoxic payload can cause damage to healthy cells, leading to adverse effects and limiting the potential use of ADCs in treating certain cancers. Further, the process of bioconjugation is complex, and there are numerous factors that can affect the stability of the final product which can impact the efficacy and safety of the ADC. The advancements in linker and payload technologies and the emergence of new manufacturing technologies helped to overcome such challenges in ADC development.

Ecosystem Analysis Antibody Drug Conjugates Market

The Kadcyla segment of the antibody drug conjugates industry held the dominant position in 2022.

On the basis of product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and Others. The Kadcyla segment dominated the antibody drug conjugate market during the forecast period. The rising prevalence of breast cancer coupled with increased approvals for the ADCs for breast cancer treatment are some of the factors driving the market growth.

Blood Cancer Segment of the antibody drug conjugates is likely to grow at significant CAGR during the forecast period.

On the basis of disease type, the global antibody drug conjugates market is segmented into breast cancer, blood cancer and others. The breast cancer segment dominated the market in 2022 owing to various factors such as increased adoption of ADCs for treatment by patient population. The increasing number of clinical trials on ADCs for breast cancer and the recent approvals of ADCs target indications, such as blood cancer, lung cancer, cervical cancer, and ovarian cancer among others is further expected to project the market growth at faster pace.

Asia Pacific region of the antibody drug conjugates industry is likely to grow at the highest CAGR during the forecast period of 2023-2028.

The antibody drug conjugates market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market, and this trend is expected to continue during the forecast period. A robust product pipeline and increased regulatory approvals of ADCs are likely to propel the market growth in the region.  Asia Pacific segment is likely to grow at a higher CAGR owing to various factors such as the increasing number of cancer cases coupled with the rise in the use of ADCs for the treatment of cancer. Furthermore, the launch of biosimilar Ujivra by Zydus is likely to have a positive impact on the market growth in the coming years.

Source: Expert Interviews, Secondary Research, Whitepapers, Journals, Magazines, and MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Key players in the antibody drug conjugates market include F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), Zydus Group (India)

Scope of the Antibody Drug Conjugates Industry:

This report categorizes the antibody drug conjugates market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

By Disease Type

• Breast Cancer
• Blood Cancer
• Others

By Linker Type

• Non-Cleavable
• Cleavable

By Target

• HER2
• CD22
• CD30
• Others

By Payload Type

• MMAE/auristatin
• calicheamicin
• Maytansinoids
• Others

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa

Recent Developments of Antibody Drug Conjugates Industry

• In July 2023, ImmunoGen, Inc., entered into a multi-target license and option agreement with ImmunoBiochem to develop next-generation antibody-drug conjugates.
• In July 2023, BeiGene and DualityBio entered into a partnership to advance differentiated antibody drug conjugate (ADC) therapy for solid tumors.
• In June 2023, Lonza acquired Synaffix B.V. a biotechnology company involved in commercializing clinical-stage technology platforms for the development of antibody drug conjugates.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst